At the ISPOR Warsaw 2019 regional conference, a panel examined country experiences with managed entry agreements and their impact on improving access to innovative oncology therapies.
This article summarizes the lessons learned from implementing managed entry and multi-year, multi-indication agreements in different regional contexts.
Busting a myth: Is achieving US drug prices in Europe impossible?
To answer this question, the authors searched for evidence in the individual countries. Germany and the UK, for example, are the two European countries where...